002940.SHE Zhejiang Anglikang Pharmaceutical Co Ltd Class A
- Market cap
- CNY 4.76B
- P/E
- 43.7x
- P/B
- 2.59x
- ROE
- 5.0%
- Dividend yield
- 1.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002940.SHE undervalued?
Graham number002940.SHE trades 124.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Anglikang Pharmaceutical Co Ltd Class A fundamental analysis
No fundamental analysis for Zhejiang Anglikang Pharmaceutical Co Ltd Class A yet.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such as isoflurane and sevoflurane; and anti-androgen intermediates, including finast…
Full company profileZhejiang Anglikang Pharmaceutical Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 672M | 873M | 1.26B | 1.40B | 1.29B | 1.38B | 1.57B | 1.62B | 1.51B | 1.42B | 1.20B |
| Gross Profit | 216M | 464M | 875M | 1.02B | 968M | 892M | 894M | 707M | 588M | 562M | 450M |
| Operating Income | 89.3M | 124M | 131M | 155M | 212M | 174M | 149M | 212M | 160M | 203M | 129M |
| EBITDA | 134M | 160M | 165M | 176M | 204M | 198M | 203M | 241M | 205M | 270M | 115M |
| Net Income | 82.2M | 101M | 109M | 112M | 164M | 120M | 127M | 138M | 80.3M | 125M | 83.5M |
| EPS | 0.58 | 0.71 | 0.73 | 0.59 | 0.86 | 0.61 | 0.64 | 0.69 | 0.40 | 0.62 | 0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 728M | 907M | 1.47B | 1.38B | 1.94B | 2.08B | 2.60B | 3.02B | 2.97B | 2.95B | 2.92B |
| Total Liabilities | 401M | 512M | 499M | 369M | 563M | 609M | 950M | 1.19B | 1.18B | 1.08B | 1.01B |
| Shareholders' Equity | 311M | 370M | 919M | 965M | 1.32B | 1.34B | 1.50B | 1.59B | 1.53B | 1.63B | 1.66B |
| Cash & Short-term Investments | 59.7M | 139M | 618M | 628M | 854M | 749M | 805M | 870M | 733M | 687M | 497M |
| Total Debt | 113M | 80.0M | 15.0M | 69.8M | 10.0M | 98.1M | 345M | 557M | 465M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 142M | 194M | 134M | 213M | 199M | 198M | 185M | 277M | 254M | 244M | - |
| Capital Expenditure | 25.8M | 54.8M | 68.2M | 75.6M | 91.0M | 87.3M | 68.8M | 125M | 94.5M | 49.9M | 60.8M |
| Free Cash Flow | 116M | 139M | 65.4M | 138M | 108M | 110M | 116M | 152M | 159M | 194M | 173M |
| Ratios | |||||||||||
| ROE | 26.4% | 27.3% | 11.8% | 11.6% | 12.4% | 9.0% | 8.5% | 8.7% | 5.2% | 7.7% | 5.0% |
| ROA | 11.3% | 11.1% | 7.4% | 8.1% | 8.4% | 5.8% | 4.9% | 4.6% | 2.7% | 4.3% | 2.9% |
| Net Profit Margin | 12.2% | 11.6% | 8.7% | 8.0% | 12.7% | 8.7% | 8.1% | 8.5% | 5.3% | 8.8% | 7.0% |
| Debt to Equity | 0.36x | 0.22x | 0.02x | 0.07x | 0.01x | 0.07x | 0.23x | 0.35x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A dividends
- Dividend yield
- 1.21%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 45.9%
- Ex-dividend date
- Jun 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 57.6M | 0.29 | 45.9% |
| 2024 | CNY 58.8M | 0.29 | 73.2% |
| 2023 | CNY 61.6M | 0.31 | 44.5% |
| 2022 | CNY 28.2M | 0.14 | 22.1% |
| 2021 | CNY 46.9M | 0.24 | 39.2% |
| 2020 | CNY 90.0M | 0.47 | 55.0% |
| 2019 | CNY 67.5M | 0.36 | 60.1% |
| 2018 | CNY 1.93M | 0.01 | 1.8% |
| 2017 | CNY 45.2M | 0.32 | 44.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.45:1 on May 19, 2023.
Who owns Zhejiang Anglikang Pharmaceutical Co Ltd Class A
- Insiders 49.27%
- Institutions 0.84%
- Public & others 49.89%
- Shares outstanding 202M
- Free float 100.0M
Zhejiang Anglikang Pharmaceutical Co Ltd Class A company profile
- Company name
- Zhejiang Anglikang Pharmaceutical Co Ltd Class A
- Ticker
- 002940.SHE
- ISIN
- CNE100003GC2
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,236
- Fiscal year end
- December
- Address
- No. 1000, North Shengzhou Avenue, Shengzhou, China, 312400
- Phone
- 86 575 8312 3228
- Website
- alkpharm.com
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such as isoflurane and sevoflurane; and anti-androgen intermediates, including finasteride and dutasteride. It also provides chemical agents consisting of anti-infective preparations, such as cefixime and cefadroxil capsules, cefaclor sustained-release tablets, cefaclor granules, and cefalexin capsules; cardiovascular preparations, including levamlodipine besylate and amlodipine besylate tablets, nifedipine sustained-release and sacubitril/valsartan sodium tablets, and measartan potassium and ticagrelor tablets; anesthetic and analgesic preparations, such as sevoflurane inhalation, liprocaine cream, and pregabalin capsules; nephropathy preparations, including compound a-keto acid tablets, levocarnitine oral solutions, and lanthanum carbonate chewable tablets; oryzanol and doxofylline tablets; and other products. In addition, the company offers specialty intermediates, such as plant-derived cholesterol and its derivatives, plant-derived vitamin D3, and plant-derived 25-hydroxyvitamin D3. Further, it provides lyophilized powder injections, steroidal biological products, and plant extracts; penicillin; and active pharmaceutical ingredients (APIs) for respiratory system, digestive system, and pain indications. Additionally, the company engages in biotechnology promotion activities. The company serves pharmaceutical companies, commercial and pharmaceutical distribution companies, chemical and nutritional companies, and feed companies. Zhejiang AngLiKang Pharmaceutical CO.,LTD. was founded in 2001 and is headquartered in Shengzhou, China.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A management
6- Mr. Guo Gang ZhengGM & Director · born 1973
- Mr. Huihao LuDeputy GM & Vice Chairman of the Board · born 1970
- Ms. Song Ying MaoFinancial Director & Accounting Supervisor · born 1978
- Mr. Liming SunDeputy GM & Secretary of the Board · born 1977
- Mr. Guo Dong YangDeputy General Manager · born 1967
- Mr. Jinwen LuoDeputy General Manager · born 1974